Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Tayyaba Hasan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0871-6057; OpenAlex author ID A5058184923; NIH RePORTER profile ID 1877772. Sources: OpenAlex.

Their work

Papers
28 (first author 0, last author 18)
Trials
0
Grants
1
Labs led
1
Collaborators
43
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 5 papers · 2020: 2 papers · 2021: 3 papers · 2022: 3 papers · 2023: none · 2024: 3 papers · 2025: 1 paper · 2026: 3 papers, 1 grant

Papers 28

  1. Markers of immune activation and immunotherapy responsiveness are increased in 3D Pancreatic cancer organoids when primed with photodynamic- and chemo-therapy. Last author DOI 10.1016/j.tranon.2026.102716↗
  2. Myeloid–Treg Crosstalk Disruption by Photochemical Activation and Immune Checkpoint Therapy Triples Median Survival in a Pancreatic Cancer Model Co-author DOI 10.21203/rs.3.rs-8912367/v1↗
  3. Photodynamic priming enhances anti-PD1 therapy responses in patient-derived pancreatic cancer organoid immune cocultures. Last author DOI 10.3389/fimmu.2026.1805948↗
  4. Photodynamic priming with red light triggers adaptive immune responses in a pancreatic cancer mouse model. Last author DOI 10.1016/j.jphotobiol.2025.113126↗
  5. Immunofluorescence profiling of collagen subtypes is a predictor of treatment outcomes in pancreatic cancer. Last author DOI 10.1016/j.jphotobiol.2023.112811↗
  6. Minocycline and photodynamic priming significantly improve chemotherapy efficacy in heterotypic spheroids of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.jphotobiol.2024.112910↗
  7. Efficacy of photodynamic therapy using 5-aminolevulinic acid-induced photosensitization is enhanced in pancreatic cancer cells with acquired drug resistance. Co-author DOI 10.1016/j.pdpdt.2024.104362↗
  8. Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancreatic Cancer. Last author DOI 10.1002/advs.202104594↗
  9. Orthotopic Models of Pancreatic Cancer to Study PDT. Last author DOI 10.1007/978-1-0716-2099-1_12↗
  10. Photoimmunotherapy Retains Its Anti-Tumor Efficacy with Increasing Stromal Content in Heterotypic Pancreatic Cancer Spheroids. Last author DOI 10.1021/acs.molpharmaceut.2c00260↗
  11. EUS-guided verteporfin photodynamic therapy for pancreatic cancer. Co-author DOI 10.1016/j.gie.2021.02.027↗
  12. CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment. Co-author DOI 10.1088/1361-6560/ac1458↗
  13. Photodynamic priming with triple-receptor targeted nanoconjugates that trigger T cell-mediated immune responses in a 3D in vitro heterocellular model of pancre… Last author DOI 10.1515/nanoph-2021-0304↗
  14. High-Resolution Ex Vivo Elastography to Characterize Tumor Stromal Heterogeneity In Situ in Pancreatic Adenocarcinoma. Co-author DOI 10.1109/tbme.2019.2963562↗
  15. NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer. Last author DOI 10.3390/jcm9082390↗
  16. Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer. Last author DOI 10.1016/j.biomaterials.2019.119421↗
  17. Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towar… Last author DOI 10.1021/acs.nanolett.9b00859↗
  18. Size-dependent Tumor Response to Photodynamic Therapy and Irinotecan Monotherapies Revealed by Longitudinal Ultrasound Monitoring in an Orthotopic Pancreatic C… Last author DOI 10.1111/php.13016↗
  19. Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment. Co-author DOI 10.1117/1.jbo.24.11.118001↗
  20. Tracking Photodynamic- and Chemotherapy-Induced Redox-State Perturbations in 3D Culture Models of Pancreatic Cancer: A Tool for Identifying Therapy-Induced Met… Last author DOI 10.3390/jcm8091399↗
  21. Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids. Last author DOI 10.18632/oncotarget.24425↗
  22. Collagen Complexity Spatially Defines Microregions of Total Tissue Pressure in Pancreatic Cancer. Co-author DOI 10.1038/s41598-017-10671-w↗
  23. Simultaneous delivery of cytotoxic and biologic therapeutics using nanophotoactivatable liposomes enhances treatment efficacy in a mouse model of pancreatic ca… Last author DOI 10.1016/j.nano.2015.08.007↗
  24. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-15-0391↗
  25. Perfusion CT estimates photosensitizer uptake and biodistribution in a rabbit orthotopic pancreatic cancer model: a pilot study. Co-author DOI 10.1016/j.acra.2014.12.014↗
  26. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2014.95↗
  27. CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. Co-author DOI 10.1088/0031-9155/59/8/1911↗
  28. Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Last author DOI 10.1002/lsm.21093↗

Grants 1

  1. Core A: Administration, Integration, Education and Career Development P01CA084203↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian W. Pogue · 11 shared papers, 2014–2025 · strength 1.20
  2. Bryan Quilty Spring · 3 shared papers, 1 shared grant, 2016–2026 · strength 1.14
  3. Girgis Obaid · 7 shared papers, 2019–2024 · strength 1.13
  4. Mohammad Ahsan Saad · 4 shared papers, 2022–2026 · strength 1.02
  5. Shazia Bano · 6 shared papers, 2019–2024 · strength 1.01
  6. Pushpamali De Silva · 4 shared papers, 2021–2026 · strength 0.99
  7. Vinay Chandrasekhara · 3 shared papers, 2025–2026 · strength 0.75
  8. Kenneth K. Wang · 4 shared papers, 2019–2025 · strength 0.62
  9. Stephen Pereira · 1 shared grant, 2026 · strength 0.58
  10. Kenneth K Wang · 1 shared grant, 2026 · strength 0.58
  11. Guillermo J Tearney · 1 shared grant, 2026 · strength 0.58
  12. Edward V Maytin · 1 shared grant, 2026 · strength 0.58
  13. Brian William Pogue · 1 shared grant, 2026 · strength 0.58
  14. Brett E Bouma · 1 shared grant, 2026 · strength 0.58
  15. Vinay Chandrasekhara · 1 shared grant, 2026 · strength 0.58
  16. Stephen Pereira · 1 shared grant, 2026 · strength 0.58
  17. Huang‐Chiao Huang · 3 shared papers, 2016–2024 · strength 0.42
  18. Anne‐Laure Bulin · 4 shared papers, 2018–2019 · strength 0.40
  19. Mans Broekgaarden · 4 shared papers, 2018–2019 · strength 0.40
  20. Mari A. Mino-Kenudson · 2 shared papers, 2022–2024 · strength 0.38
  21. Jonathan P. Celli · 3 shared papers, 2011–2024 · strength 0.38
  22. Fernanda V. Cabral · 1 shared paper, 2026 · strength 0.36
  23. Stephen P. Pereira · 5 shared papers, 2011–2021 · strength 0.30
  24. Haidong Dong · 1 shared paper, 2026 · strength 0.27
  25. Andrew Scott Liss · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.